The scenarios below are analyst-designed stress tests. No probabilities are assigned.
| Scenario | Evidence or trigger to monitor | Proposed response | Exposure to quantify |
|---|---|---|---|
| Scheduled list-price reset occurs | Manufacturer implementation and actual distributor quotations | Reconcile contract pricing and inventory treatment | Stock exposure, credits and clinic acquisition cost |
| A patient-access offer changes | Revised manufacturer eligibility, price or refill terms | Refresh affordability estimates and patient communications | Patient expenditure, clinic support workload and refunds |
| A pharmacy pauses new orders | Written notice or deterioration in agreed performance measures | Activate a pre-screened alternative and reconcile open orders | Unfulfilled prescriptions, deposits and transition work |
| A proposed compounded route becomes unusable | Counsel’s assessment of applicable regulatory or legal developments | Stop new commitments; implement a clinically supervised access transition | Minimum payments, stranded expenditure and communication costs |
| Bridge processing creates additional rework | Aggregate rejection and clarification reasons | Correct routing and documentation before expanding the workflow | Staff minutes per completed case and unresolved patient demand |
Board question: What evidence would cause us to pause a route, and who has authority to act? Decide this before the disruption rather than during it.
Explore the table row by row
A working view of the research
Scheduled list-price reset occurs
- Evidence or trigger to monitor
- Manufacturer implementation and actual distributor quotations
- Proposed response
- Reconcile contract pricing and inventory treatment
- Exposure to quantify
- Stock exposure, credits and clinic acquisition cost
Sources cited on this page
See the section’s source register for the research context.
Section sources →